PolyPhotonix is a biophotonic research company developing healthcare solutions in therapeutics, diagnostics and imaging, using photonics as an enabling solution.
Established in 2009, the company is currently focused on light therapy treatments for macular eye disease and has successfully brought its first medical device to market from early product development through clinical research and on to commercialisation in the UK and selected foreign markets.
The Noctura 400 Sleep Mask is a transformational treatment for Diabetic Retinopathy and Macular Oedema, which are serious and sight-threatening complications of diabetes. The introduction of the mask could save the NHS £1 billion compared to current pharmaceutical treatments.
Click here to listen to the interview with Richard Kirk of PolyPhotonix on BBC Radio Tees.